Global cardiac safety services market is projected to register a CAGR of 15.4% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.
Market Segmentation:
Global Cardiac Safety Services Market, By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute) Industry Trends and Forecast to 2029.
Some of the major factors contributing to the growth of the global cardiac safety services market are:
Increase in the number of clinical trials being conducted
Increase in prevalence of cardiovascular diseases
Market Players:
The key market players for global cardiac safety services market are listed below:
Biotrial
Banook Group
Bioclinica
Certara L.P.
Celerion, Inc.
Laboratory Corporation of America Holdings
Medpace Holdings, Inc.
Ncardia AG
Richmond Pharmacology
PhysioStim
IQVIA
TABLE OF CONTENTS
1 INTRODUCTION 27
- 1.1 OBJECTIVES OF THE STUDY 27
- 1.2 MARKET DEFINITION 27
- 1.3 OVERVIEW OF GLOBAL CARDIAC SAFETY SERVICES MARKET 27
- 1.4 LIMITATIONS 28
- 1.5 MARKETS COVERED 29
2 MARKET SEGMENTATION 31
- 2.1 MARKETS COVERED 31
- 2.2 GEOGRAPHICAL SCOPE 32
- 2.3 YEARS CONSIDERED FOR THE STUDY 33
- 2.4 CURRENCY AND PRICING 33
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 34
- 2.6 MULTIVARIATE MODELLING 37
- 2.7 SERVICES LIFELINE CURVE 37
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 38
- 2.9 DBMR MARKET POSITION GRID 39
- 2.10 MARKET END USER GRID 41
- 2.11 VENDOR SHARE ANALYSIS 42
- 2.12 SECONDARY SOURCES 43
- 2.13 ASSUMPTIONS 43
3 EXECUTIVE SUMMARY 44
4 PREMIUM INSIGHTS 47
- 4.1 PORTERS FIVE FORCES 48
- 4.2 PESTEL ANALYSIS 49
5 EPIDEMIOLOGY 50
- 5.1 INCIDENCE OF ALL BY GENDER 50
- 5.2 TREATMENT RATE 51
- 5.3 MORTALITY RATE 51
- 5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 52
6 INDUSTRY INSIGHT 53
- 6.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 53
- 6.2 PATENT ANALYSIS 54
- 6.3 PATENT FLOW DIAGRAM 55
- 6.4 KEY PATIENT ENROLLMENT STRATEGIES 55
- 6.5 PRICING STRATEGY 58
7 GLOBAL CARDIAC SAFETY SERVICES MARKET: REGULATIONS 59
8 MARKET OVERVIEW 62
- 8.1 DRIVERS 64
- 8.1.1 INCREASE IN THE NUMBER OF CLINICAL TRIALS 64
- 8.1.2 INCREASE IN HEALTHCARE EXPENDITURE AND FUNDING 64
- 8.1.3 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 65
- 8.1.4 INCREASE IN R&D ACTIVITIES 65
- 8.2 RESTRAINTS 66
- 8.2.1 HIGH COST OF CARDIAC SAFETY EVALUATION 66
- 8.2.2 STRICT REGULATORY 66
- 8.3 OPPORTUNITIES: 67
- 8.3.1 INCREASE IN NEW DRUG DEVELOPMENT 67
- 8.3.2 RISE IN THE EXPANSION OF THE CARDIAC SAFETY SERVICES 68
- 8.4 CHALLENGES 68
- 8.4.1 TIME-CONSUMING PROCEDURE 68
- 8.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CARDIAC SAFETY EVALUATION 69
9 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY SERVICES 70
- 9.1 OVERVIEW 71
- 9.2 ECG/HOLTER MEASUREMENTS 75
- 9.3 BLOOD PRESSURE MEASUREMENTS 75
- 9.4 IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES 76
- 9.4.1 HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS 77
- 9.4.1.1 1 CONCENTRATIONS 77
- 9.4.1.2 4 CONCENTRATIONS 77
- 9.4.2 COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) 78
- 9.4.2.1 3 CONCENTRATIONS 78
- 9.4.2.2 5 CONCENTRATIONS 78
- 9.4.3 IN VITRO HERG ASSAY 78
- 9.4.4 OTHERS 78
- 9.5 CARDIOVASCULAR IMAGING 78
- 9.6 REAL TIME TELEMETRY MONITORING 79
- 9.7 CENTRAL OVER-READ OF ECGS 80
- 9.8 NON-INVASIVE CARDIAC IMAGING 80
- 9.9 PHYSIOLOGIC STRESS TESTING 81
- 9.10 THOROUGH QT STUDIES 82
- 9.11 TQT AND EXPOSURE RESPONSE MODELLING 82
- 9.12 PLATELET AGGREGATION 83
- 9.13 OTHERS 84
10 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY PHASE 85
- 10.1 OVERVIEW 86
- 10.2 PHASE I 89
- 10.3 PHASE II 89
- 10.4 PHASE III 90
11 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY TYPE 91
- 11.1 OVERVIEW 92
- 11.2 INTEGRATED SERVICES 95
- 11.3 STANDALONE SERVICES 96
12 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY END USER 97
- 12.1 OVERVIEW 98
- 12.2 PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES 101
- 12.3 CONTRACT RESEARCH ORGANIZATIONS 101
- 12.4 ACADEMIC AND RESEARCH INSTITUTE 102
13 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY REGION 103
- 13.1 OVERVIEW 104
- 13.2 NORTH AMERICA 109
- 13.2.1 U.S. 117
- 13.2.2 CANADA 120
- 13.2.3 MEXICO 123
- 13.3 EUROPE 126
- 13.3.1 GERMANY 134
- 13.3.2 FRANCE 137
- 13.3.3 U.K. 140
- 13.3.4 ITALY 143
- 13.3.5 SPAIN 146
- 13.3.6 TURKEY 149
- 13.3.7 RUSSIA 152
- 13.3.8 NETHERLANDS 155
- 13.3.9 SWITZERLAND 158
- 13.3.10 BELGIUM 161
- 13.3.11 REST OF EUROPE 164
- 13.4 ASIA-PACIFIC 165
- 13.4.1 CHINA 173
- 13.4.2 JAPAN 176
- 13.4.3 SOUTH KOREA 179
- 13.4.4 INDIA 182
- 13.4.5 AUSTRALIA 185
- 13.4.6 SINGAPORE 188
- 13.4.7 THAILAND 191
- 13.4.8 MALAYSIA 194
- 13.4.9 INDONESIA 197
- 13.4.10 PHILIPPINES 200
- 13.4.11 REST OF ASIA-PACIFIC 203
- 13.5 SOUTH AMERICA 204
- 13.5.1 BRAZIL 212
- 13.5.2 ARGENTINA 215
- 13.5.3 REST OF SOUTH AMERICA 218
- 13.6 MIDDLE EAST AND AFRICA 219
- 13.6.1 SOUTH AFRICA 227
- 13.6.2 SAUDI ARABIA 230
- 13.6.3 U.A.E. 233
- 13.6.4 ISRAEL 236
- 13.6.5 EGYPT 239
- 13.6.6 REST OF MIDDLE EAST AND AFRICA 242
14 GLOBAL CARDIAC SAFETY SERVICES MARKET: COMPANY LANDSCAPE 243
- 14.1 COMPANY SHARE ANALYSIS: GLOBAL 243
- 14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 244
- 14.3 COMPANY SHARE ANALYSIS: EUROPE 245
- 14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 246
15 COMPANY PROFILE 247
- 15.1 EUROFINS SCIENTIFIC 247
- 15.1.1 COMPANY SNAPSHOT 247
- 15.1.2 REVENUE ANALYSIS 248
- 15.1.3 COMPANY SHARE ANALYSIS 248
- 15.1.4 PRODUCT PORTFOLIO 248
- 15.1.5 RECENT DEVELOPMENTS 249
- 15.1.5.1 AGREEMENTS 249
- 15.1.5.2 ACQUISITION 249
- 15.2 PPD INC. (SUBSIDIARY OF THERMO FISHER SCIENTIFIC INC) 250
- 15.2.1 COMPANY SNAPSHOT 250
- 15.2.2 REVENUE ANALYSIS 250
- 15.2.3 COMPANY SHARE ANALYSIS 251
- 15.2.4 PRODUCT PORTFOLIO 251
- 15.2.5 RECENT DEVELOPMENT 251
- 15.3 KONINKLIJKE PHILIPS N.V. 252
- 15.3.1 COMPANY SNAPSHOT 252
- 15.3.2 REVENUE ANALYSIS 252
- 15.3.3 COMPANY SHARE ANALYSIS 253
- 15.3.4 PRODUCT PORTFOLIO 253
- 15.3.5 RECENT DEVELOPMENT 253
- 15.4 IQVIA 254
- 15.4.1 COMPANY SNAPSHOT 254
- 15.4.2 REVENUE ANALYSIS 254
- 15.4.3 COMPANY SHARE ANALYSIS 255
- 15.4.4 PRODUCT PORTFOLIO 255
- 15.4.5 RECENT DEVELOPMENTS 255
- 15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS 256
- 15.5.1 COMPANY SNAPSHOT 256
- 15.5.2 REVENUE ANALYSIS 256
- 15.5.3 COMPANY SHARE ANALYSIS 257
- 15.5.4 PRODUCT PORTFOLIO 257
- 15.5.5 RECENT DEVELOPMENTS 257
- 15.5.5.1 NEW LABORATORY 257
- 15.5.5.2 ACQUISITION 257
- 15.6 BANOOK 258
- 15.6.1 COMPANY SNAPSHOT 258
- 15.6.2 PRODUCT PORTFOLIO 258
- 15.6.3 RECENT DEVELOPMENT 258
- 15.7 BIOTRIAL 259
- 15.7.1 COMPANY SNAPSHOT 259
- 15.7.2 PRODUCT PORTFOLIO 259
- 15.7.3 RECENT DEVELOPMENT 259
- 15.7.3.1 NEW CENTER OPENING 259
- 15.8 CELERION 260
- 15.8.1 COMPANY SNAPSHOT 260
- 15.8.2 PRODUCT PORTFOLIO 260
- 15.8.3 RECENT DEVELOPMENT 260
- 15.8.3.1 NEW CENTER OPENING 260
- 15.9 CERTARA 261
- 15.9.1 COMPANY SNAPSHOT 261
- 15.9.2 REVENUE ANALYSIS 261
- 15.9.3 PRODUCT PORTFOLIO 262
- 15.9.4 RECENT DEVELOPMENTS 262
- 15.9.4.1 CONTRACT 262
- 15.9.4.2 ACQUISITION 262
- 15.10 CLARIO 263
- 15.10.1 COMPANY SNAPSHOT 263
- 15.10.2 PRODUCT PORTFOLIO 263
- 15.10.3 RECENT DEVELOPMENT 263
- 15.10.3.1 PRODUCT EXPANSION 263
- 15.11 MEDPACE 264
- 15.11.1 COMPANY SNAPSHOT 264
- 15.11.2 REVENUE ANALYSIS 264
- 15.11.3 PRODUCT PORTFOLIO 265
- 15.11.4 RECENT DEVELOPMENTS 265
- 15.11.4.1 ACQUISITION 265
- 15.12 NCARDIA 266
- 15.12.1 COMPANY SNAPSHOT 266
- 15.12.2 PRODUCT PORTFOLIO 266
- 15.12.3 RECENT DEVELOPMENT 266
- 15.12.3.1 PARTNERSHIP 266
- 15.13 NEXEL CO., LTD 267
- 15.13.1 COMPANY SNAPSHOT 267
- 15.13.2 PRODUCT PORTFOLIO 267
- 15.13.3 RECENT DEVELOPMENTS 267
- 15.13.3.1 JOINT VENTURE 267
- 15.13.3.2 PARTNERSHIP 268
- 15.14 PHYSIOSTIM 269
- 15.14.1 COMPANY SNAPSHOT 269
- 15.14.2 PRODUCT PORTFOLIO 269
- 15.14.3 RECENT DEVELOPMENT 269
- 15.14.3.1 PARTNERSHIP 269
- 15.15 RICHMOND PHARMACOLOGY 270
- 15.15.1 COMPANY SNAPSHOT 270
- 15.15.2 PRODUCT PORTFOLIO 270
- 15.15.3 RECENT DEVELOPMENT 270
- 15.16 SGS SA 271
- 15.16.1 COMPANY SNAPSHOT 271
- 15.16.2 REVENUE ANALYSIS 271
- 15.16.3 PRODUCT PORTFOLIO 272
- 15.16.4 RECENT DEVELOPMENT 272
- 15.16.4.1 ACQUISITION 272
- 15.17 SHANGHAI MEDICILON INC. 273
- 15.17.1 COMPANY SNAPSHOT 273
- 15.17.2 PRODUCT PORTFOLIO 273
- 15.17.3 RECENT DEVELOPMENTS 273
- 15.17.3.1 PARTNERSHIP 273
- 15.17.3.2 PARTNERSHIP 274
16 QUESTIONNAIRE 275
17 RELATED REPORTS 277